	Bénéfice Avant Impôts		Date
Abbott	USD 2.36B	178M	2025-12
Acadia Pharmaceuticals	USD 26.32M	18.28M	2025-12
Agios Pharmaceuticals	USD -109.06M	5.62M	2025-12
Akebia Therapeutics	USD 6.11M	28.92M	2025-03
Alnylam Pharmaceuticals	USD 161.14M	77.83M	2025-12
AstraZeneca	USD 3.24B	117M	2025-09
BioMarin Pharmaceutical	USD -26.32M	324.19M	2025-09
Coherus Biosciences	USD -47.4M	14.9M	2025-03
Eli Lilly	USD 7.23B	456M	2025-09
Esperion Therapeutics	USD 67.66M	3.6M	2024-09
Halozyme Therapeutics	USD 218.96M	14.02M	2025-09
Illumina	USD 220M	86M	2025-09
Insmed	USD -326.93M	41.77M	2025-12
Ironwood Pharmaceuticals	USD 68.02M	30.2M	2025-09
J&J	USD 4.97B	2.53B	2025-12
Lexicon Pharmaceuticals	USD -53.43M	5.03M	2024-06
MacroGenics	USD 16.82M	52.97M	2025-09
MannKind	USD -20.93M	28.71M	2025-12
Merck	USD 6.74B	22M	2025-09
Moderna	USD -187M	631M	2025-09
Novartis	USD 4.2B	335M	2025-09
PTC Therapeutics	USD -139.08M	116.01M	2025-12
Puma Biotechnology	USD 20.61M	24.76M	2024-09
Sarepta Therapeutics	USD -407.67M	213.63M	2025-12
Thermo Fisher Scientific	USD 2.12B	295M	2025-12
Ultragenyx Pharmaceutical	USD -128M	51.54M	2025-12
United Therapeutics	USD 444M	6M	2025-12
Vanda Pharmaceuticals	USD -22.92M	16.68M	2024-12

Lexicon Pharmaceuticals Bénéfice Avant Impôts - Les valeurs actuelles, des données historiques, des prévisions, des statistiques, des tableaux et le calendrier économique - Mar 2026.